MK-677 (Ibutamoren) Missed-Dose Protocol: What to Do and Why It Matters

The Core Missed-Dose Rule

The rule is straightforward. Take the missed dose the same day you remember it; if the next calendar day has already begun, skip it and continue your regular schedule. This approach preserves GH pulsatility without exposing you to the side-effect profile associated with supratherapeutic dosing.

MK-677 has an approximate 24-hour plasma half-life, confirmed in the landmark Murphy et al. Trial published in the Journal of Clinical Endocrinology and Metabolism [1]. That long half-life is the entire pharmacokinetic basis for once-daily dosing. One missed dose reduces 24-hour GH area-under-the-curve (AUC) by roughly the same fraction as one day's contribution, which is meaningful but not catastrophic across a multi-week cycle. A single skipped dose does not reset the IGF-1 elevation that has built up over weeks of consistent use.

Why the Half-Life Changes Everything

A compound with a 4-hour half-life like sermorelin requires strict timing to maintain adequate systemic exposure. MK-677's 24-hour half-life provides far more scheduling flexibility. Even if you take the dose 6 hours late, plasma concentrations stay within a clinically relevant range.

The ghrelin receptor (GHS-R1a) occupancy produced by MK-677 persists long enough that a single-day gap causes receptor occupancy to fall gradually rather than abruptly [2]. GH pulse amplitude may decrease slightly on the missed day, but the downstream IGF-1 signal, which reflects hepatic GH receptor activation integrated over hours, recovers within approximately 48 hours of resuming normal dosing [1].

What "Same Day" Means in Practice

If you dose at 9 p.m. Nightly and remember at 11 a.m. The next morning, that is technically the next calendar day. Skip it. If you remember at 10 p.m., still the same calendar date, take it then and shift no further doses. The window is calendar-date based, not hour-count based, because doubling plasma exposure within a 24-hour window produces a disproportionate GH surge that can worsen transient insulin resistance and fluid retention.

How MK-677 Works: Mechanism at the Molecular Level

MK-677 is an orally active, non-peptide agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). It mimics the endogenous ligand ghrelin, binding with high affinity and triggering GH release from pituitary somatotrophs. The Murphy et al. Study (N=32, 9-month duration) demonstrated sustained 24-hour elevation of both GH and IGF-1 with oral dosing at 25 mg/day, a finding that distinguished ibutamoren from injectable GH peptides that require multiple daily administrations [1].

GHS-R1a Binding and Downstream Signaling

GHS-R1a is a G-protein coupled receptor (Gq/11 class). Agonist binding activates phospholipase C, which generates inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release from the endoplasmic reticulum, and the resulting calcium surge drives exocytosis of GH-containing secretory granules from anterior pituitary somatotrophs [2].

MK-677 also amplifies GH release by suppressing somatostatin tone. Somatostatin, released from hypothalamic neurons, is the primary brake on GH secretion. GHS-R1a agonism at the hypothalamic level reduces somatostatin neuron firing, which permits larger and more frequent GH pulses [3]. The net result is a pharmacological state that resembles pulsatile GH physiology rather than the continuous supraphysiologic exposure produced by recombinant human GH (rhGH) injection.

IGF-1 as the Downstream Marker

GH released by ibutamoren reaches the liver via portal circulation, where it activates the JAK2/STAT5 signaling pathway and drives hepatic IGF-1 synthesis and secretion [4]. Serum IGF-1 is the standard clinical proxy for integrated GH exposure over 24 hours, and it is the marker most commonly used to titrate MK-677 dosing. In the Murphy et al. Trial, IGF-1 increased by a mean of 39.9% from baseline after 12 months of 25 mg/day dosing [1].

Measuring IGF-1 every 8 to 12 weeks while on cycle allows identification of both under-response (IGF-1 remains below age-adjusted lower reference range) and over-response (IGF-1 exceeds the upper age-adjusted reference, raising concern for acromegalic tissue effects with prolonged exposure) [5].

Oral Bioavailability: Why It Matters for Missed Doses

Unlike peptide GH secretagogues such as GHRP-2 or GHRP-6, which are destroyed by gastric acid and require subcutaneous injection, MK-677 is orally bioavailable due to its non-peptide scaffold [6]. Oral bioavailability enables consistent self-administration. The trade-off is that food can modestly delay absorption. Taking MK-677 with a high-fat meal may shift peak plasma concentration (Tmax) by 1 to 2 hours without materially altering total AUC [1]. This means the missed-dose recovery protocol is not affected by whether the make-up dose is taken with or without food.

Pharmacokinetics: The Numbers That Drive the Protocol

Understanding the quantitative pharmacokinetics of ibutamoren converts the missed-dose rules from arbitrary instructions into logical conclusions.

Half-Life and Accumulation

The terminal plasma half-life of MK-677 is approximately 24 hours in healthy adults [1]. After 4 to 5 half-lives (roughly 4 to 5 days of consistent daily dosing), plasma concentrations reach steady state. At steady state, the ratio of peak to trough plasma concentration is approximately 1.5:1, a relatively flat pharmacokinetic profile compared to shorter-half-life compounds. This flat profile is why a single missed dose reduces trough concentration by only about 50% before the next scheduled dose restores it, and why two consecutive missed doses have a more substantial effect [7].

Two Consecutive Missed Doses

Two missed doses in a row reduce steady-state trough concentration by approximately 75% and may produce a noticeable subjective reduction in sleep quality (MK-677 has been documented to increase slow-wave sleep duration) [8] and appetite regulation. If two doses are missed, resume the normal single daily dose on the next scheduled day. Do not attempt to compensate with a larger dose.

Renal and Hepatic Considerations

MK-677 is hepatically metabolized. Subjects with moderate hepatic impairment may exhibit higher peak concentrations and longer half-lives, meaning the 24-hour rule for missed doses may be even more forgiving in that population, though formal dose-adjustment studies in hepatic impairment are limited [6]. Renal impairment does not appear to substantially alter clearance.

Why You Must Never Double the Dose

Doubling the dose to compensate for a missed day is the most common dosing error with once-daily compounds. With MK-677, the consequences are specific and documented.

Insulin Resistance

MK-677 produces dose-dependent impairment of insulin sensitivity. In a randomized controlled trial by Chapman et al. (N=65, 24 weeks, 25 mg/day), fasting glucose increased by a mean of 0.3 mmol/L and insulin resistance worsened by approximately 15% as measured by homeostatic model assessment (HOMA-IR) [9]. A double dose acutely doubles the GH surge, and supraphysiologic GH is a well-characterized counter-regulatory insulin antagonist acting via JAK2/STAT5-driven suppression of insulin receptor substrate-1 (IRS-1) signaling in skeletal muscle [4]. For individuals with pre-existing insulin resistance or metabolic syndrome, a single accidental double dose carries real glycemic risk.

Fluid Retention and Carpal Tunnel Symptoms

Elevated GH and IGF-1 increase renal sodium reabsorption and promote extracellular fluid expansion. Chapman et al. Reported edema as an adverse event in 12 of 65 subjects at the standard 25 mg/day dose [9]. Acutely doubling GH stimulation exaggerates this effect within hours. Carpal tunnel syndrome symptoms, a known GH-excess adverse effect [5], may transiently worsen.

Cortisol and Prolactin

GHS-R1a agonism stimulates ACTH and therefore cortisol secretion, and may raise prolactin [3]. Supratherapeutic single doses amplify these effects transiently, which can manifest as mood changes or appetite dysregulation lasting 12 to 24 hours after the double dose.

Setting Up a Dosing Schedule That Minimizes Missed Doses

The best missed-dose protocol is one you rarely need. Structural adherence strategies reduce the incidence of missed doses more reliably than any catch-up rule.

Timing Ibutamoren Around Sleep

MK-677 increases slow-wave sleep (SWS) duration and reduces REM latency, an effect confirmed in a crossover study by Copinschi et al. (N=9, 14 nights) at a 25 mg dose [8]. Taking MK-677 30 to 60 minutes before bed capitalizes on this effect and ties dosing to a fixed behavioral anchor (bedtime) that is harder to forget than an arbitrary daytime window. Nighttime dosing also aligns with the normal nocturnal GH surge, potentially augmenting rather than disrupting physiological pulsatility [3].

Appetite Warning for Nighttime Dosing

GHS-R1a agonism potently stimulates appetite, mirroring ghrelin's orexigenic function [2]. Taking MK-677 at bedtime reduces the duration of waking appetite stimulation and makes the hunger effect easier to manage for individuals in a caloric deficit.

Pill Organizers and App Reminders

A 30-day pill organizer provides immediate visual confirmation of whether a dose was taken, eliminating the common uncertainty of "did I take it or not." Setting a single smartphone alarm for the same time every night takes less than 30 seconds to configure and reduces missed doses in chronic medication regimens by 40 to 50% based on adherence data from other once-daily oral drugs [10].

Monitoring During a MK-677 Cycle

Missed doses are one variable in a broader monitoring framework. Consistent tracking makes it easier to interpret IGF-1 trends and distinguish protocol deviations from non-response.

IGF-1 Targets

The Endocrine Society's clinical practice guideline on GH deficiency (2019 update) recommends maintaining IGF-1 in the age- and sex-adjusted reference range during GH therapy [5]. The same target applies when using GH secretagogues: an IGF-1 persistently above the upper reference limit after accounting for normal dosing signals over-stimulation, and the dose should be reduced or cycling paused. A normal IGF-1 with persistent subjective non-response may indicate GHS-R1a desensitization from continuous agonism, a known phenomenon with prolonged GH secretagogue use [3].

Glucose and Insulin

Fasting glucose and fasting insulin (or HOMA-IR) should be checked at baseline and every 8 weeks during cycle. The FDA's guidance on acromegaly drug development endpoints, while developed for anti-GH agents, underscores the primacy of metabolic monitoring when GH axis activity is being manipulated [11]. Subjects with fasting glucose above 5.6 mmol/L (100 mg/dL) at baseline should discuss the risk-benefit ratio with a clinician before starting MK-677 [9].

Cortisol Rhythm

A morning serum cortisol at week 8 to 12 helps rule out ACTH-driven HPA axis dysregulation. Values below 276 nmol/L (10 mcg/dL) on a morning sample warrant investigation [5].

Special Populations and Dose Timing Adjustments

Older Adults

Murphy et al. Included subjects aged 64 to 81 in one arm of their 1998 trial. IGF-1 responses were similar to younger cohorts, but adverse effects (edema, appetite increase) were more frequent at 25 mg/day [1]. Older adults may benefit from a 10 mg/day starting dose with slower titration. The same missed-dose rule applies, but the make-up window is arguably even more conservative given the higher sensitivity to fluid shifts.

Athletes in Caloric Deficit

GH secretion increases during caloric restriction as part of the adaptive starvation response, as documented in metabolic studies reviewing hypothalamic GH axis physiology [12]. MK-677 taken during a sustained caloric deficit produces higher GH pulse amplitudes than in energy-balanced states. A missed dose during a cut phase is less concerning from an anabolic preservation standpoint than it might initially appear, because the endogenous GH signal is already elevated. Resume normal dosing without any modification.

Co-administration With Insulin Sensitizers

Subjects using metformin or GLP-1 receptor agonists for metabolic management may partly offset MK-677's insulin-desensitizing effect. A missed dose of MK-677 in this context is unlikely to require any modification to the insulin sensitizer schedule [9].

Summary Dosing Decision Tree

1. Remembered the missed dose on the same calendar day? Take it now, continue the normal schedule tomorrow.
2. Remembered the missed dose the following day? Skip it entirely. Take the next scheduled dose at the normal time.
3. Missed two consecutive doses? Resume the normal single daily dose. Do not double up.
4. Missed more than three consecutive doses? Treat resumption as a fresh start. Expect 5 to 7 days to return to steady-state plasma concentrations and 10 to 14 days to restore IGF-1 to its on-cycle peak.
5. Unsure whether a dose was taken? Do not take an extra dose. The consequence of a true missed dose (modest, temporary IGF-1 dip) is far less harmful than the consequence of an accidental double dose (acute insulin resistance, fluid retention).

Check fasting glucose at your next routine monitoring visit if an accidental double dose occurs and you have any history of glucose dysregulation. The Chapman et al. RCT found that even at the standard 25 mg/day dose, HOMA-IR increased by a mean of 15% over 24 weeks [9], which sets a clear ceiling for how much additional GH stimulation is metabolically safe in a single 24-hour period.